<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pancrelipase: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pancrelipase: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pancrelipase: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9737" href="/d/html/9737.html" rel="external">see "Pancrelipase: Drug information"</a> and <a class="drug drug_patient" data-topicid="11241" href="/d/html/11241.html" rel="external">see "Pancrelipase: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F206069"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Creon;</li>
<li>Pancreaze;</li>
<li>Pancrelipase (Lip-Prot-Amyl);</li>
<li>Pertzye;</li>
<li>Viokace;</li>
<li>Zenpep</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912177"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cotazym;</li>
<li>Creon;</li>
<li>Pancrease MT;</li>
<li>Ultrase;</li>
<li>Ultrase MT;</li>
<li>Viokase</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060868"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme, Pancreatic</span>;</li>
<li>
<span class="list-set-name">Pancreatic Enzyme</span></li></ul></div>
<div class="block don drugH1Div" id="F53462532"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Adjust dose based on body weight, clinical symptoms, and stool fat content. Allow several days between dose adjustments.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6efdb41-27fd-4293-a56f-bd1534068475">Pancreatic insufficiency due to cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic insufficiency due to cystic fibrosis:</b> Limited data available: Oral: Lipase: 2,000 to 5,000 units per feeding of formula or breast milk. Reported dose range: 492 to 3,727 units lipase/<b>kg</b> per feeding. While a daily maximum of 10,000 units/kg/<b>day</b> was previously recommended based on limited evidence, this daily dose is insufficient for many patients; doses up to 28,139 units lipase/kg/<b>day </b>have been safely reported; in one evaluation, the average daily dose was 12,259 units lipase/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19914445','lexi-content-ref-23809508','lexi-content-ref-29176494','lexi-content-ref-33839912','lexi-content-ref-29122829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19914445','lexi-content-ref-23809508','lexi-content-ref-29176494','lexi-content-ref-33839912','lexi-content-ref-29122829'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F206085"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Adjust dose based on body weight, clinical symptoms, and stool fat content. Allow several days between dose adjustments. Doses of lipase &gt;6,000 units/kg/meal are associated with colonic stricture and should be decreased.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6efdb41-27fd-4293-a56f-bd1534068475">Pancreatic insufficiency due to cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic insufficiency due to cystic fibrosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General dosing recommendations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Dosage requirements may fluctuate as diet transitions to more solid foods.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;6 months: Oral: Lipase: 2,000 to 5,000 units per feeding of formula or breast milk. Reported dose range: 492 to 3,727 units/kg per feeding. While a daily maximum of 10,000 units/kg/<b>day</b> was previously recommended based on limited evidence, this daily dose is insufficient for many patients; doses up to 28,139 units lipase/kg/<b>day </b>have been safely reported; in one evaluation, the average daily dose was 12,259 units lipase/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19914445','lexi-content-ref-23809508','lexi-content-ref-29176494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19914445','lexi-content-ref-23809508','lexi-content-ref-29176494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months: Oral: Lipase: 2,000 to 5,000 units per feeding of formula or breast milk. Reported dose range: 313 to 3,612 units/kg per feeding. While a daily maximum of 10,000 units/kg/<b>day</b> was previously recommended based on limited evidence, this daily dose is insufficient for many patients; doses up to 26,388 units lipase/kg/<b>day </b>have been safely reported; in one evaluation, the average daily dose was 10,689 units lipase/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19914445','lexi-content-ref-23809508','lexi-content-ref-29176494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19914445','lexi-content-ref-23809508','lexi-content-ref-29176494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;2 years: Oral: Initial dose: Lipase 1,000 units/kg/meal. Dosage range: Lipase 1,000 to 2,500 units/kg/meal. Maximum daily dose: Lipase 10,000 units/kg/<b>day</b> or lipase 4,000 units/g of fat/day. Higher dosing similar to infant dosing (Lipase: 2,000 to 5,000 units per feeding of formula, breast milk, or per breastfeeding) may be necessary in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19914445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19914445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 to &lt;4 years: Oral: Initial dose: Lipase 1,000 units/kg/meal. Dosage range: Lipase 1,000 to 2,500 units/kg/meal. Maximum daily dose: Lipase 10,000 units/kg/<b>day</b> or lipase 4,000 units/g of fat/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: Oral: Initial dose: Lipase 500 units/kg/meal. Dosage range: Lipase 500 to 2,500 units/kg/meal. Maximum daily dose: Lipase 10,000 units/kg/<b>day</b> or lipase 4,000 units per g of fat/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a2b82fd-df2c-468c-be06-d18045415296">Pancreatic enzyme supplementation, enteral tube feedings</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic enzyme </b>
<b>supplementation, enteral tube feedings</b>: Infants, Children, and Adolescents: Limited data available: Enteral: 1,000 to 4,000 units lipase/g of fat provided by feeds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21508176','lexi-content-ref-27599607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21508176','lexi-content-ref-27599607'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51151408"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; enzymes contain purines that may increase blood uric acid levels.</p></div>
<div class="block dohp drugH1Div" id="F51151409"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F206071"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9737" href="/d/html/9737.html" rel="external">see "Pancrelipase: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing should not exceed recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines. Dosing is based on lipase units and can be dosed based on grams of fat ingested (which is more likely to mimic normal pancreatic response) or by weight. Adjust dose based on body weight, clinical symptoms, stool fat content, and the fat content of the diet. Allow several days between dose adjustments. Total daily dose reflects ~3 meals per day and 2 to 3 snacks per day, with half the mealtime dose given with a snack. Doses of lipase &gt;2,500 units/kg/meal, lipase &gt;10,000 units/kg/<b>day</b>, or lipase &gt;4,000 units/g fat daily should be used with caution and only with documentation of effectiveness by 3-day fecal fat measures indicating a significantly improved coefficient of fat absorption. High doses of lipase &gt;6,000 units/kg/meal for ≥6 months are associated with fibrosing colonopathy; immediately decrease or titrate down to a lower dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CFF.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CFF.2022'])">Ref</a></span>). Refer to institutional policies and procedures.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd8d22e9-df43-47c4-b6b0-b420091e9995">Occluded enteral feeding tubes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Occluded enteral feeding tubes (off-label use): Note: </b>Use of enteric-coated tablets/capsules may reduce effectiveness of clearing enteral tube (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34340577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34340577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Enteral feeding tube (not for oral administration):</b></i> 1 tablet (nonenteric coated; lipase 10,440 units) mixed with sodium bicarbonate and warm water; instill in enteral feeding tube using light pressure and clamp for 5 to 15 minutes; then use warm sterile water to aspirate or flush the feeding tube; repeat if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34340577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34340577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dea08db3-5c45-4fdc-8116-c56b04d7930f">Pancreatic insufficiency, cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic insufficiency, cystic fibrosis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (Creon, Pancreaze, Pertzye, Zenpep): Initial: Lipase 500 units/kg/<b>meal</b>. For each snack, administer half the prescribed mealtime dose. Usual dose: Lipase 500 to 4,000 units/<b>g of fat</b> daily <b>or</b> lipase 500 to 2,500 units/kg/<b>meal</b> and lipase 250 to 1,250 units/kg/<b>snack</b>. Maximum dose: Lipase ≤2,500 units/kg/<b>meal or</b> lipase ≤10,000 units/kg/<b>day or</b> lipase &lt;4,000 units/<b>g of fat</b> daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CFF.2022','lexi-content-ref-27068495','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CFF.2022','lexi-content-ref-27068495','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7102b18e-e223-4123-9333-1ace4199458e">Pancreatic insufficiency, chronic pancreatitis or pancreatectomy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic insufficiency, chronic pancreatitis or pancreatectomy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Creon: <b>Oral:</b> Initial: Lipase 500 units/kg/<b>meal</b> with individualized dosage titrations. For each snack, administer half the prescribed mealtime dose. Usual dose: Lipase 25,000 to 50,000 units/<b>meal</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022720','lexi-content-ref-28281169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022720','lexi-content-ref-28281169'])">Ref</a></span>). Maximum dose: Lipase ≤2,500 units/kg/<b>meal or</b> lipase ≤10,000 units/kg/<b>day or</b> lipase &lt;4,000 units/<b>g of fat</b> daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Viokace: <b>Note:</b> Must be administered with a proton pump inhibitor (PPI) since it is not enteric coated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Lipase 500 units/kg/<b>meal</b> with individualized dosage titration. For each snack, administer half the prescribed mealtime dose. Usual dose: Lipase 25,000 to 50,000 units/<b>meal </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022720','lexi-content-ref-28281169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022720','lexi-content-ref-28281169'])">Ref</a></span>). Maximum dose: Lipase ≤2,500 units/kg/<b>meal or</b> lipase ≤10,000 units/kg/<b>day or</b> lipase &lt;4,000 units/<b>g of fat</b> daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a66766ba-49f3-4585-9ac3-35432ccb251b">Pancreatic insufficiency, pancreatic cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic insufficiency (exocrine), pancreatic cancer (off-label dosing):</b>
<b>Oral:</b> Initial: Lipase 25,000 to 50,000 units/<b>meal</b>
<b>or</b> lipase 1,000 units/kg/<b>day or</b> 4,000 units per 5 to 7 <b>g of fat</b> at each meal; titrate dose based on relief of symptoms. For each snack, administer half the prescribed mealtime dose. Maximum dose: Lipase 2,500 units/kg/<b>meal</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19149324','lexi-content-ref-32631175','lexi-content-ref-30799929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19149324','lexi-content-ref-32631175','lexi-content-ref-30799929'])">Ref</a></span>). <b>Note: </b>Viokace must be administered with a PPI because it is not enteric coated.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991848"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution.</p></div>
<div class="block doha drugH1Div" id="F50989141"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F206044"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal signs and symptoms (including abdominal pain, abnormal stools, constipation, diarrhea, duodenitis, dyspepsia, flatulence, frequent bowel movements, gastritis, nausea, vomiting)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Choledocholithiasis, early satiety, gallbladder disease (hydrocholecystis), pruritus ani</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal cyst</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, nasopharyngitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (Ferrone 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal obstruction (distal intestinal obstruction syndrome [DIOS])</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Carcinoma (recurrence), neutropenia (Amoateng 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, severe hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fibrosis (fibrosing colonopathy) (Ferrone 2007, Mack 2004)</p></div>
<div class="block coi drugH1Div" id="F206057"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Hypersensitivity to pancrelipase or any component of the formulation; acute pancreatitis; acute exacerbation of chronic pancreatitis.</p></div>
<div class="block war drugH1Div" id="F206041"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fibrosing colonopathy: Fibrosing colonopathy, advancing to colonic strictures, has been reported (rarely). Risk may be increased with high doses, prolonged use, and in pediatric patients with cystic fibrosis; however, the mechanism is unknown. Doses of lipase &gt;6,000 units/kg/meal have been associated with colonic stricture in children &lt;12 years. Patients taking doses of lipase &gt;6,000 units/kg/meal should be examined and the dose decreased. Doses of lipase &gt;2,500 units/kg/meal, lipase &gt;10,000 units/kg/day, or lipase &gt;4,000 units/g fat daily should be used with caution and only with documentation of effectiveness by 3-day fecal fat measures indicating a significantly improved coefficient of fat absorption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe, allergic reactions (eg, anaphylaxis, asthma, hives, pruritus) have rarely been observed; use with caution in patients hypersensitive to pork proteins, taking into consideration the patient's overall clinical needs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mucosal irritation: Crushing or chewing the contents of the capsules or tablets, or mixing the capsule contents with foods outside of product labeling, may cause early release of the enzymes, causing irritation of the oral mucosa and/or loss of enzyme activity. When mixing the contents of capsules with food, the mixture should be swallowed immediately and followed with water or juice to ensure complete ingestion. Pancrelipase should not be mixed in foods with pH &gt;4.5.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pork: Products are derived from porcine pancreatic glands. Transmission of porcine viruses, and diseases caused by novel or unidentified viruses, is theoretically a risk; however, testing and/or inactivation or removal of certain viruses, reduces the risk. There have been no cases of transmission of an infectious illness reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gout, hyperuricemia: Use caution in patients with gout or hyperuricemia; porcine-derived products contain purines which may increase uric acid concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatic cancer: According to guidelines from the American Society of Clinical Oncology, patients with pancreatic cancer (potentially curable, locally advanced, or metastatic) who experience exocrine pancreatic insufficiency may require pancreatic enzyme replacement therapy to improve digestion and nutrient absorption and limit weight loss (Balaban 2016; Khorana 2016; Sohal 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment; porcine-derived products contain purines which may increase uric acid concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Brand interchangeability: Available brand products are <b>not</b> interchangeable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Viokace tablets may contain lactose; use with caution in patients with lactose intolerance.</p></div>
<div class="block foc drugH1Div" id="F206051"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, delayed release, bicarbonate buffered enteric coated microspheres, oral [porcine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: Lipase 4,000 USP units, protease 14,375 USP units, and amylase 15,125 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: Lipase 8,000 USP units, protease 28,750 USP units, and amylase 30,250 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: Lipase 16,000 USP units, protease 57,500 USP units, and amylase 60,500 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: Lipase 24,000 USP units, protease 86,250 USP units, and amylase 90,750 USP units</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, delayed release, enteric-coated beads, oral [porcine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 3,000 USP units, protease 10,000 USP units, and amylase 14,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 5,000 USP units, protease 17,000 USP units, and amylase 24,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 10,000 USP units, protease 32,000 USP units, and amylase 42,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 15,000 USP units, protease 47,000 USP units, and amylase 63,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 20,000 USP units, protease 63,000 USP units, and amylase 84,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 25,000 USP units, protease 79,000 USP units, and amylase 105,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 40,000 USP units, protease 126,000 USP units, and amylase 168,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: Lipase 40,000 USP units, protease 136,000 USP units, and amylase 218,000 USP units [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, delayed release, enteric coated microspheres, oral [porcine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, delayed release, enteric coated microtablets, oral [porcine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: Lipase 2600 USP units, protease 8800 USP units, and amylase 15,200 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: Lipase 4200 USP units, protease 14,200 USP units, and amylase 24,600 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: Lipase 10,500 USP units, protease 35,500 USP units, and amylase 61,500 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: Lipase 16,800 USP units, protease 56,800 USP units, and amylase 98,400 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: Lipase 21,000 USP units, protease 54,700 USP units, and amylase 83,900 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: Lipase 37,000 USP units, protease 97,300 USP units, and amylase 149,900 USP units</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral [porcine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Viokace: Lipase 10,440 USP units, protease 39,150 USP units, and amylase 39,150 USP units</p>
<p style="text-indent:-2em;margin-left:4em;">Viokace: Lipase 20,880 USP units, protease 78,300 USP units, and amylase 78,300 USP units</p></div>
<div class="block geq drugH1Div" id="F206037"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323605"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, enteric pellets</b> (Creon Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000-9500 unit (per each): $2.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6000-19000 unit (per each): $2.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12000-38000 unit (per each): $4.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24000-76000 unit (per each): $9.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36000-114000 unit (per each): $15.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, enteric pellets</b> (Pancreaze Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2600-8800 unit (per each): $0.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4200-14200 unit (per each): $1.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10500-35500 unit (per each): $3.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16800-56800 unit (per each): $6.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">21000-54700 unit (per each): $7.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37000-97300 unit (per each): $17.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, enteric pellets</b> (Pertzye Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000-14375 unit (per each): $2.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8000-28750 unit (per each): $3.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16000-57500 unit (per each): $6.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24000-86250 unit (per each): $9.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, enteric pellets</b> (Zenpep Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000-10000 unit (per each): $2.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000-24000 unit (per each): $2.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000-32000 unit (per each): $4.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15000-47000 unit (per each): $7.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000-63000 unit (per each): $9.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25000-79000 unit (per each): $11.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40000-126000 unit (per each): $18.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60000-189600 unit (per each): $28.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Viokace Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10440-39150 unit (per each): $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20880-78300 unit (per each): $10.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613515"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Administer with meals or snacks and swallow capsules or tablets whole with a generous amount of liquid, water, or juice. Do not crush or chew; retention in the mouth before swallowing may cause mucosal irritation and stomatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: If necessary, capsules may also be opened and contents added to a small amount of an acidic food (pH ≤4.5), such as applesauce. The food should be at room temperature and swallowed immediately after mixing. The contents of the capsule should not be crushed or chewed. Follow with water or juice to ensure complete ingestion and that no medication remains in the mouth. Creon capsules contain enteric-coated spheres which are 0.71 to 1.6 mm in diameter. Pancreaze capsules contain enteric-coated microtablets which are ~2 mm in diameter. Zenpep capsules contain enteric-coated beads which are 1.8 to 2.5 mm in diameter. Pertzye capsules contain bicarbonate buffered enteric-coated microspheres which are 0.8 to 2.2 mm in diameter.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;1 year: Avoid mixing with breast milk or infant formula. Open capsule and place the contents directly into the mouth or mix with a small amount of acidic soft food (pH ≤4.5) such as applesauce, or other commercially prepared baby food (pears or bananas) at room temperature. Administer immediately after mixing (or within 15 minutes of mixing using Pancreaze). Follow with infant formula or breast milk to ensure complete ingestion and that no medication remains in the mouth.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets (Viokace): Adults: Tablets are not enteric coated and should be taken with a proton pump inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;">Enteral feeding tube: May be administered prior to feeds, at the end of feeds, or divided and administered throughout feeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21508176','lexi-content-ref-27599607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21508176','lexi-content-ref-27599607'])">Ref</a></span>). Sodium bicarbonate has also been used to dissolve the beads (Creon, Pancreaze, Zenpep) before administering into feeding tube, although optimal regimen has not been described; may cause increase in serum bicarbonate; monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26150571','lexi-content-ref-21508176','lexi-content-ref-23753650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26150571','lexi-content-ref-21508176','lexi-content-ref-23753650'])">Ref</a></span>). Some centers crush enzymes prior to administration; however, data regarding stability are lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21508176','lexi-content-ref-27599607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21508176','lexi-content-ref-27599607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: An in vitro study demonstrated that Creon delayed-release capsules were sprinkled onto a small amount of baby food (pH &lt;4.5; applesauce or bananas manufactured by Gerber or Beech-Nut), stirred gently, and after 15 minutes administered through the following G-tubes without significant loss of lipase activity: Kimberly-Clark MIC Bolus size 18 French, Kimberly-Clark MIC-KEY size 16 French, Bard Tri-Funnel size 18 French, and Bard Button size 18 French (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21627335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21627335'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: May administer up to two 4,000 unit capsules via G-tube with a diameter of 14 French or larger. Thoroughly mix contents of one or two 4,000 unit capsules in ≥10 mL applesauce to create a uniform suspension; do not crush microspheres. Administer via a 35 mL slip tip syringe; flush with ~10 mL of water. Administer immediately after mixing; do not save for later use. If dose requires more than two 4,000 unit capsules, repeat process.</p></div>
<div class="block adm drugH1Div" id="F206054"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with meals or snacks and swallow whole with a generous amount of liquid. Do not crush or chew; retention in the mouth before swallowing may cause mucosal irritation. Administer half the prescribed dose at the start of a meal and the second half in the middle of the meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20510833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20510833'])">Ref</a></span>); for snacks, administer half the prescribed mealtime dose with each snack. The total daily dose should reflect ~3 meals plus 2 or 3 snacks per day.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules, delayed release: If necessary, capsules may be opened and contents added to a small amount (~10 mL) of soft acidic food (pH ≤4.5), such as applesauce; do not crush microspheres when mixing. The entire food content should be swallowed immediately after mixing (do not save for later use); do not chew. The food should be at room temperature (Creon). Follow with water or juice to ensure complete ingestion and that no medication remains in the mouth.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Viokace: Tablets are not enteric coated and should be taken with a proton pump inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Administration via gastrostomy (G) tube:</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: An in vitro study demonstrated that Creon delayed-release capsules sprinkled onto a small amount of baby food (pH &lt;4.5; applesauce or bananas manufactured by both Gerber and Beech-Nut) stirred gently and after 15 minutes was administered through the following G-tubes without significant loss of lipase activity: Kimberly-Clark MIC Bolus size 18 French, Kimberly-Clark MIC-KEY size 16 French, Bard Tri-Funnel size 18 French, and Bard Button size 18 French (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21627335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21627335'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: May administer up to two 4,000 unit capsules via G-tube with a diameter of 14 French or larger diameter tube. Thoroughly mix contents of one or two 4,000 unit capsules in ≥10 mL applesauce to create a uniform suspension; do not crush microspheres. Administer via a 35 mL slip tip syringe; flush with ~10 mL of water. Administer immediately after mixing; do not save for later use. If dose requires &gt; two 4,000 unit capsules, repeat.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Occluded enteral feeding tubes (off-label use):</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Crush 1 nonenteric coated tablet (lipase 10,440 units) with 1 sodium bicarbonate 325 mg tablet to a fine powder, mix in 5 mL warm sterile water, then instill in occluded enteral tube using light pressure and clamp for 5 to 15 minutes. Then, use warm sterile water to aspirate or flush the tube; a light "back and forth" motion with the syringe plunger is suggested to dislodge the clog (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34340577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34340577'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F206065"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Avoid heat. Protect from moisture. After opening, keep the container tightly closed between uses to protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Creon: Store at 15°C to 25°C (59°F to 77°F); excursions are permitted between 25°C and 40°C (77°F and 104°F) for ≤30 days. Discard if moisture conditions are &gt;70%. Bottles of 3,000 USP units of lipase must be stored and dispensed in the original container.</p>
<p style="text-indent:-2em;margin-left:2em;">Pancreaze: Store at ≤25°C (77°F). Store in the original container.</p>
<p style="text-indent:-2em;margin-left:2em;">Pancrelipase: Store at 20°C to 25°C (68°F to 77°F); brief excursions are permitted between 15°C and 40°C (59°F and 104°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Pertzye: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 40°C (59°F and 104°F) for ≤30 days. Store in the original container.</p>
<p style="text-indent:-2em;margin-left:2em;">Viokace: Store at 20°C to 25°C (68°F to 77°F); brief excursions are permitted up to 40°C (104°F) for ≤24 hours. Store in the original container.</p>
<p style="text-indent:-2em;margin-left:2em;">Zenpep:</p>
<p style="text-indent:-2em;margin-left:4em;">Original glass container: Store at 20°C to 25°C (68°F to 77°F); brief excursions are permitted between 15°C and 40°C (59°F and 104°F) for 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Repackaged HDPE container: Store at ≤30°C (86°F) for up to 6 months; brief excursions are permitted between 15°C and 40°C (59°F and 104°F) for ≤30 days.</p></div>
<div class="block meg drugH1Div" id="F7990592"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Creon: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F020725s028lbl.pdf%23page%3D16&amp;token=u33iSBQbJir3QIoHNx26xr1Y6DtDu6gxLf70q23nBQYrWvS%2FrdDqyRYgzwCwm9QmRr6KKT9e7xqrzzUThKLe8DAVHzXU0rkoEX7UEZULSUgctkDL0R19cNSEZf99g6aw&amp;TOPIC_ID=12675" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020725s028lbl.pdf#page=16</a></p>
<p style="text-indent:-2em;margin-left:4em;">Pancreaze: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022523s013lbl.pdf%23page%3D16&amp;token=n60hj27WW0ZEddIn9d0bhfQs9td8vcFHCOq1wiq0Q8hl3kAC7QjL3KN78P%2Bf%2BH45OkIywx735aGKbweRPB6ICvjbT5yz2S7uenbzlx3GvIkWcwUnyj34BpvRLhJtu%2Bg0&amp;TOPIC_ID=12675" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022523s013lbl.pdf#page=16</a></p>
<p style="text-indent:-2em;margin-left:4em;">Pertzye: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022175s008lbl.pdf%23page%3D13&amp;token=qD%2Fb51HNyBItS09KDzhC5C2vIXOVy03Fow92O8V37dH8zLG7LTNmLnjuLJsEinRPftFOg1kDKC0wDZRfS6LVvcYHwxe0WlLWjSm1otVDuaeubDnQ3wugozM2uW8bQopa&amp;TOPIC_ID=12675" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022175s008lbl.pdf#page=13</a></p>
<p style="text-indent:-2em;margin-left:4em;">Viokace: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022542s007lbl.pdf%23page%3D12&amp;token=%2FqzWlkDARwrKCHc4y47gMXpSEELhWTO8lC2Vs4Rt2mzT8y%2BVt%2FX%2FpORrS01%2B3umM6O%2BkLkB4cCySJJ83Xw%2BIIEf2j%2FlbRk3ANNmowicx2Lm2rLEKWK%2FpTah9ChMlHoEc&amp;TOPIC_ID=12675" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022542s007lbl.pdf#page=12</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zenpep: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022210s024lbl.pdf%23page%3D14&amp;token=JEr2e23IXyYfKrs5I4t9OL%2Bcb662C%2FuNm1xP9s%2FvEvV2lIgSNYVz8EJt9WFB7dxuFWpFeQ9hEshSdxM1bHNmStRpQqOMaDS5so3YbYjTOZQeC5w%2B%2B7i0564DH2Kirr%2Fe&amp;TOPIC_ID=12675" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022210s024lbl.pdf#page=14</a></p></div>
<div class="block usep drugH1Div" id="F53568203"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Creon: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis (FDA approved in infants, children, adolescents, and adults); treatment of exocrine pancreatic insufficiency due to chronic pancreatitis, pancreatectomy, or other conditions (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Pancreaze, Pertzye, Zenpep: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (FDA approved in infants, children, adolescents, and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Viokace: Treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in combination with a proton pump inhibitor (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F7828225"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pancrelipase may be confused with pancreatin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299815"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222114"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block foi drugH1Div" id="F206066"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Delayed release capsules: Enteric coated contents of delayed release capsules opened and sprinkled on alkaline foods may result in early release of pancrelipase followed by enzyme inactivation by gastric acid in the stomach after swallowing. Management: Avoid placing contents of opened capsules on alkaline food (using soft acidic foods with a pH of ≤4.5 is recommended for patients who cannot swallow capsules).</p></div>
<div class="block dic drugH1Div" id="F206061"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with meals or snacks and swallow whole with a generous amount of liquid. Capsule contents may be sprinkled on a soft acidic food with pH &lt;4.5. Vitamin supplementation should be per current guidelines for patients with cystic fibrosis. </p></div>
<div class="block pri drugH1Div" id="F7990593"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic absorption of pancrelipase is limited; significant fetal exposure is not expected following maternal use.</p>
<p style="text-indent:0em;margin-top:2em;">Pancrelipase is considered compatible for use during pregnancy (Edenborough 2008; Panchaud 2016).</p></div>
<div class="block mopp drugH1Div" id="F53568197"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Stool frequency and fat content, abdominal symptoms, nutritional intake, weight, growth, stool character, serum bicarbonate if using bicarbonate for enteral feeding tube administration.</p></div>
<div class="block pha drugH1Div" id="F206040"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pancrelipase is a natural product harvested from the porcine pancreatic glands. It contains a combination of lipase, amylase, and protease. Products are formulated to dissolve in the more basic pH of the duodenum so that they may act locally to break down fats, protein, and starch.</p></div>
<div class="block phk drugH1Div" id="F206056"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: None; acts locally in GI tract </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038716"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pancrelipase Dci</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pancrease</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Pancrease</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Digestomen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lipacreon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anase | Hattorase | Pancrease | Panga | Zenpep</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Pancrease</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pancrease</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Enzadyne | Ku-Zyme HP | Panokase | Viokace</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Creon 25000 | Creon 40000</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Prolipase</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Pankrease</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33753395">
<a name="33753395"></a>Amoateng R, Hardman B, Liu C, Austin S. Rare case of pancrelipase therapy-induced neutropaenia. <i>BMJ Case Rep</i>. 2021;14(3):e241799. doi:10.1136/bcr-2021-241799<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/33753395/pubmed" id="33753395" target="_blank">33753395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19209287">
<a name="19209287"></a>Baker SS, “Delayed Release Pancrelipase for the Treatment of Pancreatic Exocrine Insufficiency Associated With Cystic Fibrosis,” <i>Ther Clin Risk Manag</i>, 2008, 4(5):1079-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/19209287/pubmed" id="19209287" target="_blank">19209287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print May 31, 2016]. <i>J Clin Oncol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23809508">
<a name="23809508"></a>Borowitz D, Gelfond D, Maguiness K, et al. Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis. <i>J Cyst Fibros</i>. 2013. Available at http://dx.doi.org/10.1016/j.jcf2013.05.011
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/23809508/pubmed" id="23809508" target="_blank">23809508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19914445">
<a name="19914445"></a>Borowitz D, Robinson KA, Rosenfeld M, et al; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. <i>J Pediatr</i>. 2009;155:S73-S93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/19914445/pubmed" id="19914445" target="_blank">19914445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26150571">
<a name="26150571"></a>Boullata AM, Boullata JI. Pancreatic enzymes prepared in bicarbonate solution for administration through enteral feeding tubes. <i>Am J Health Syst Pharm</i>. 2015;72(14):1210-1214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/26150571/pubmed" id="26150571" target="_blank">26150571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cotazym.1">
<a name="Cotazym.1"></a>Cotazym (pancrelipase) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Creon.1">
<a name="Creon.1"></a>Creon (pancrelipase) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Creon.2">
<a name="Creon.2"></a>Creon (pancrelipase) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CFF.2022">
<a name="CFF.2022"></a>Cystic Fibrosis Foundation (CFF). Pancreatic enzymes clinical care guidelines. https://www.cff.org/pancreatic-enzymes-clinical-care-guidelines#recommendations. Accessed February 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19149324">
<a name="19149324"></a>Damerla V, Gotlieb V, Larson H, Saif MW. Pancreatic enzyme supplementation in pancreatic cancer. <i>J Support Oncol</i>. 2008;6(8):393-396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/19149324/pubmed" id="19149324" target="_blank">19149324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18024241">
<a name="18024241"></a>Edenborough FP, Borgo G, Knoop C, et al; European Cystic Fibrosis Society. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(suppl 1):S2-S32. doi:10.1016/j.jcf.2007.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/18024241/pubmed" id="18024241" target="_blank">18024241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21508176">
<a name="21508176"></a>Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. <i>Nutr Clin Prac</i>. 2011;26(3): 349-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/21508176/pubmed" id="21508176" target="_blank">21508176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17542772">
<a name="17542772"></a>Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. <i>Pharmacotherapy</i>. 2007;27(6):910-920. doi:10.1592/phco.27.6.910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/17542772/pubmed" id="17542772" target="_blank">17542772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022720">
<a name="32022720"></a>Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG clinical guideline: chronic pancreatitis. <i>Am J Gastroenterol</i>. 2020;115(3):322-339. doi:10.14309/ajg.0000000000000535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/32022720/pubmed" id="32022720" target="_blank">32022720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29176494">
<a name="29176494"></a>Gelfond D, Heltshe SL, Skalland M, et al. Pancreatic enzyme replacement therapy use in infants with cystic fibrosis diagnosed by newborn screening. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(4):657-663. doi:10.1097/MPG.0000000000001829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/29176494/pubmed" id="29176494" target="_blank">29176494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32631175">
<a name="32631175"></a>Iglesia D, Avci B, Kiriukova M, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. <i>United European Gastroenterol J</i>. 2020;8(9):1115-1125. doi:10.1177/2050640620938987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/32631175/pubmed" id="32631175" target="_blank">32631175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247221">
<a name="27247221"></a>Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print May 31, 2016]. <i>J Clin Oncol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/27247221/pubmed" id="27247221" target="_blank">27247221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34340577">
<a name="34340577"></a>Kurish HP, Gabriel JM, Bruck CL, Stumpf JL. Efficacy of a Viokace pancreatic enzyme protocol for clearing occluded enteral feeding tubes: a quality assurance evaluation. <i>J Pharm Pract</i>. Published online August 2, 2021. doi:10.1177/08971900211036590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/34340577/pubmed" id="34340577" target="_blank">34340577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30799929">
<a name="30799929"></a>Landers A, Brown H, Strother M. The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study. <i>Palliat Care</i>. 2019;12:1178224218825270. doi:10.1177/1178224218825270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/30799929/pubmed" id="30799929" target="_blank">30799929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15455984">
<a name="15455984"></a>Mack EH, Brett AS, Brown D. Fibrosing colonopathy in an adult cystic fibrosis patient after discontinuing pancreatic enzyme therapy. <i>South Med J</i>. 2004;97(9):901-904. doi:10.1097/01.SMJ.0000129939.14179.FE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/15455984/pubmed" id="15455984" target="_blank">15455984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33839912">
<a name="33839912"></a>Münch A, Bührer C, Longardt AC. Digestive enzyme replacement relieves growth failure in preterm infants with poor exocrine pancreatic function: a retrospective case series. <i>Eur J Pediatr</i>. 2021;180(9):2951-2958. doi:10.1007/s00431-021-04069-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/33839912/pubmed" id="33839912" target="_blank">33839912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23753650">
<a name="23753650"></a>Nicolo M, Stratton KW, Rooney W, et al. Pancreatic enzyme therapy for enterally fed patients with cystic fibrosis. <i>Nutr Clin Prac</i>. 2013;28(4): 485-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/23753650/pubmed" id="23753650" target="_blank">23753650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26942733">
<a name="26942733"></a>Panchaud A, Di Paolo ER, Koutsokera A, et al. Safety of drugs during pregnancy and breastfeeding in cystic fibrosis Patients. <i>Respiration</i>. 2016;91(4):333-348. doi:10.1159/000444088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/26942733/pubmed" id="26942733" target="_blank">26942733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pancrease.1">
<a name="Pancrease.1"></a>Pancrease (pancrelipase) [product monograph]. Oakville, Ontario, Canada: Vivus Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pancreaze.1">
<a name="Pancreaze.1"></a>Pancreaze (pancrelipase) [prescribing information]. Campbell, CA: Vivus LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-XGen.1">
<a name="XGen.1"></a>Pancrelipase (pancrelipase) [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals; April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pertzye.1">
<a name="Pertzye.1"></a>Pertzye (pancrelipase) [prescribing information]. Bethlehem, PA: Digestive Care, Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28281169">
<a name="28281169"></a>Ramsey ML, Conwell DL, Hart PA. Complications of chronic pancreatitis. <i>Dig Dis Sci</i>. 2017;62(7):1745-1750. doi:10.1007/s10620-017-4518-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/28281169/pubmed" id="28281169" target="_blank">28281169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27599607">
<a name="27599607"></a>Schwarzenberg SJ, Hempstead SE, McDonald CM, et al. Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. <i>J Cyst Fibros</i>. 2016;15(6):724-735. doi:10.1016/j.jcf.2016.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/27599607/pubmed" id="27599607" target="_blank">27599607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21627335">
<a name="21627335"></a>Shlieout G, Koerner A, Maffert M, et al, “Administration of CREON Pancrelipase Pellets via Gastrostomy Tube is Feasible With No Loss of Gastric Resistance or Lipase Activity,” <i>Clin Drug Investig</i>, 2011, 31(7):e1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/21627335/pubmed" id="21627335" target="_blank">21627335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20510833">
<a name="20510833"></a>Sikkens EC, Cahen DL, Kuipers EJ, Bruno MJ. Pancreatic enzyme replacement therapy in chronic pancreatitis. <i>Best Pract Res Clin Gastroenterol</i>. 2010;24(3):337-347. doi:10.1016/j.bpg.2010.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/20510833/pubmed" id="20510833" target="_blank">20510833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247222">
<a name="27247222"></a>Sohal DP, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print May 31, 2016]. <i>J Clin Oncol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/27247222/pubmed" id="27247222" target="_blank">27247222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18442507">
<a name="18442507"></a>Stallings VA, Stark LJ, Robinson KA, et al, “Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults With Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review,” <i>J Am Diet Assoc</i>, 2008, 108(5):832-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/18442507/pubmed" id="18442507" target="_blank">18442507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24436458">
<a name="24436458"></a>Stumpf JL, Kurian RM, Vuong J, Dang K, Kraft MD. Efficacy of a Creon delayed-release pancreatic enzyme protocol for clearing occluded enteral feeding tubes. <i>Ann Pharmacother</i>. 2014;48(4):483-487. doi:10.1177/1060028013515435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/24436458/pubmed" id="24436458" target="_blank">24436458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7906805">
<a name="7906805"></a>Taylor CG, “Colonic Strictures in Cystic Fibrosis,” <i>Lancet</i>, 1994, 343(8898):615-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/7906805/pubmed" id="7906805" target="_blank">7906805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27068495">
<a name="27068495"></a>Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. <i>Clin Nutr</i>. 2016;35(3):557-577. doi:10.1016/j.clnu.2016.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/27068495/pubmed" id="27068495" target="_blank">27068495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Viokace.1">
<a name="Viokace.1"></a>Viokace (pancrelipase) [prescribing information]. Bridgewater, NJ: Nestle HealthCare Nutrition Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Viokace.2">
<a name="Viokace.2"></a>Viokace (pancrelipase) [product monograph]. Mont-Saint-Hilaire, Quebec, Canada: Aptalis Pharma Canada Inc; June 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenpep.1">
<a name="Zenpep.1"></a>Zenpep (pancrelipase) [prescribing information]. Bridgewater, NJ: Nestle HealthCare Nutrition Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29122829">
<a name="29122829"></a>Ziegler JO, Maas C, Bernhard W, Arand J, Poets CF, Franz AR. Retrospective cohort analysis on pancreatic enzyme substitution in very low birthweight infants with postnatal growth failure. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2018;103(5):F485-F489. doi:10.1136/archdischild-2017-313278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pancrelipase-pediatric-drug-information/abstract-text/29122829/pubmed" id="29122829" target="_blank">29122829</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12675 Version 177.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
